WO2009069017A1 - Barrière contre les cellules sanguines pour un dispositif à flux latéral - Google Patents

Barrière contre les cellules sanguines pour un dispositif à flux latéral Download PDF

Info

Publication number
WO2009069017A1
WO2009069017A1 PCT/IB2008/053708 IB2008053708W WO2009069017A1 WO 2009069017 A1 WO2009069017 A1 WO 2009069017A1 IB 2008053708 W IB2008053708 W IB 2008053708W WO 2009069017 A1 WO2009069017 A1 WO 2009069017A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
lateral flow
zone
flow device
ester
Prior art date
Application number
PCT/IB2008/053708
Other languages
English (en)
Inventor
John Gavin Macdonald
Molly K. Smith
Original Assignee
Kimberly-Clark Worldwide, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kimberly-Clark Worldwide, Inc. filed Critical Kimberly-Clark Worldwide, Inc.
Publication of WO2009069017A1 publication Critical patent/WO2009069017A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components

Definitions

  • Red blood cells typically constitute about half of the volume of a blood sample. Unless the red blood cells are substantially removed, their presence can affect clinical assay results that are sensitive to color. Whole blood also can interfere chemically. For example, hemoglobin that is released from red blood cells can affect the performance of certain clinical assays by virtue of the iron heme group, which can act as a catalyst in some chemical reactions.
  • the conventional manner of separating plasma from red blood cells is by centrifugation.
  • recent advances in clinical test methods has led to the development of rapid test devices that can be used by untrained individuals outside of a laboratory setting. Centrifugation is not practical for use in these procedures.
  • a lateral flow device for detecting the presence of an analyte in a whole blood sample.
  • the device comprises a barrier zone for separating red blood cells from the whole blood sample and a detection zone for detecting the analyte.
  • the detection zone is located downstream from the barrier zone and in fluid communication therewith.
  • the barrier zone is formed from a blood cell barrier composition that comprises an unsaturated aliphatic acid or ester thereof having a carbon chain of at least C 8 and more than one carbon-carbon double bond.
  • a method for detecting the presence of an analyte in a whole blood sample comprises providing a lateral flow device that comprises a barrier zone and a detection zone in fluid communication therewith, wherein the barrier zone is formed from a blood cell barrier composition that comprises an unsaturated aliphatic acid or ester thereof having a carbon chain of at least C 8 and more than one carbon-carbon double bond.
  • the barrier zone is contacted with the whole blood sample so that red blood cells are separated from blood plasma.
  • the blood plasma flows to the detection zone and presence of the analyte is detected within the detection zone.
  • Fig. 1 is a schematic illustration of one embodiment of a lateral flow assay device that may be employed in the present invention. Repeat use of references characters in the present specification and drawing is intended to represent same or analogous features or elements of the invention. Detailed Description of Representative Embodiments
  • analytes generally refers to a substance to be detected.
  • analytes may include antigenic substances, haptens, antibodies, and combinations thereof.
  • Analytes include, but are not limited to, toxins, organic compounds, proteins, peptides, microorganisms, amino acids, nucleic acids, hormones, steroids, vitamins, drugs (including those administered for therapeutic purposes as well as those administered for illicit purposes), drug intermediaries or byproducts, bacteria, virus particles and metabolites of or antibodies to any of the above substances.
  • analytes include ferritin; creatinine kinase MB (CK-MB); digoxin; phenytoin; phenobarbitol; carbamazepine; vancomycin; gentamycin; theophylline; valproic acid; quinidine; luteinizing hormone (LH); follicle stimulating hormone (FSH); estradiol, progesterone; C-reactive protein; lipocalins; IgE antibodies; cytokines; vitamin B2 micro-globulin; glycated hemoglobin (GIy.
  • ferritin creatinine kinase MB
  • CK-MB creatinine kinase MB
  • digoxin phenytoin
  • phenobarbitol carbamazepine
  • vancomycin gentamycin
  • theophylline valproic acid
  • quinidine quinidine
  • LH luteinizing hormone
  • FSH follicle stimulating hormone
  • Hb Cortisol; digitoxin; N- acetylprocainamide (NAPA); procainamide; antibodies to rubella, such as rubella- IgG and rubella IgM; antibodies to toxoplasmosis, such as toxoplasmosis IgG (Toxo-lgG) and toxoplasmosis IgM (Toxo-lgM); testosterone; salicylates; acetaminophen; hepatitis B virus surface antigen (HBsAg); antibodies to hepatitis B core antigen, such as anti-hepatitis B core antigen IgG and IgM (Anti-HBC); human immune deficiency virus 1 and 2 (HIV 1 and 2); human T-cell leukemia virus 1 and 2 (HTLV); hepatitis B e antigen (HBeAg); antibodies to hepatitis B e antigen (Anti-HBe); influenza virus; thyroid stimulating hormone (TSH); thyroxine (T
  • Drugs of abuse and controlled substances include, but are not intended to be limited to, amphetamine; methamphetamine; barbiturates, such as amobarbital, secobarbital, pentobarbital, phenobarbital, and barbital; benzodiazepines, such as librium and Valium; cannabinoids, such as hashish and marijuana; cocaine; fentanyl; LSD; methaqualone; opiates, such as heroin, morphine, codeine, hydromorphone, hydrocodone, methadone, oxycodone, oxymorphone and opium; phencyclidine; and propoxyhene.
  • Other potential analytes may be described in U.S. Patent Nos. 6,436,651 to Everhart, et al. and 4,366,241 to Tom et al.
  • the present invention is directed to a lateral flow device for analyzing a whole blood sample. More specifically, the lateral flow device contains a porous membrane that defines a barrier zone for separating red blood cells from blood plasma (includes plasma in which clotting factors haven been removed), which may then flow to a subsequent detection zone for analysis.
  • the barrier zone is particularly effective for blood samples having a relatively low volume, such as less than about 100 microliters, in some embodiments less than about 25 microliters, and in some embodiments, less than about 10 microliters.
  • whole blood drops obtained from patients with a lancet from low-pain areas may have a volume of from about 0.1 to about 5 microliters.
  • the barrier zone is formed from a blood cell barrier composition that includes an unsaturated aliphatic fatty acid or an ester thereof.
  • unsaturated aliphatic fatty acid or an ester thereof include an unsaturated aliphatic fatty acid or an ester thereof.
  • peroxides e.g., hydrogen peroxide
  • the released peroxides are believed to induce the formation of echinocytes or "crenated" blood cells.
  • Crenation is the contraction or formation of abnormal notchings around the edges of a cell after exposure to a hypertonic solution, which causes a net movement of water out of the cell through osmosis and thus a decrease in the volume of the cell cytoplasm.
  • the crenated red blood cells are distorted in shape and less flexible and malleable than normal red blood cells, making them less able to penetrate into the pores of the porous membrane of the lateral flow device. Consequently, the stiffer, less flexible cells cannot move easily into the porous and become trapped at the surface of the membrane, while the liquid components of the sample flow and penetrate through the membrane to the detection zone for analysis.
  • the unsaturated aliphatic fatty acid (or ester of) of the blood cell barrier composition has a carbon chain of at least C 8 , in some embodiments at least C-io, in some embodiments at least Ci 5 , and in some embodiments, Ci 8 -C26-
  • the aliphatic acid or ester also typically has more than one carbon-carbon double bond, such as at least 2, in some embodiments at least 3, and in some embodiments, at least 4.
  • Table 1 lists various suitable unsaturated fatty acids that may be employed arranged in three groups: omega-6, omega-3, and omega-9, wherein the term "omega" signifies where the first double bond in the carbon backbone of the fatty acid occurs. Omega-6 signifies, for instance, that the first double bond occurs at the sixth carbon from the end of the fatty acid (i.e., the omega minus 6 position).
  • omega-3 and -6 fatty acids tend to function best in separating red blood cells as they generally contain a large numbers of unsaturated bonds.
  • linoleic acid is stored usually in the form of glycerol and found in the seeds of certain plants, such as grapes, flax, safflowers, and peanuts, and fish.
  • the highest levels of linoleic acid are in safflower (carthame) seeds (68-80%), grape seeds (65-73%), and pumpkin seed oil (45-60%).
  • Table 2 provides a list of some examples of natural seed oils and their linoleic and linolenic acid content, respectively, which may be employed in the barrier zone of the present invention.
  • the unsaturated acids or esters thereof typically constitute from about 0.01 wt.% to about 20 wt.%, in some embodiments from about 0.1 wt.% to about 10 wt.%, and in some embodiments, from about 0.5 wt.% to about 5 wt.% of the blood cell barrier composition.
  • the composition may also contain other ingredients if desired.
  • the unsaturated aliphatic acid or ester thereof may be used as a primary oxidizing agent in conjunction with a secondary oxidizing agent that enhances the reaction rate of the aliphatic acid.
  • a secondary oxidizing agent may include, for example, a stabilized peroxide (e.g., urea peroxide).
  • the secondary oxidizing agent helps to accelerate the rate at which cyclic peroxide is formed. As more peroxide develops, the secondary oxidizing agent feeds a self-catalyzing reaction, accelerating the reaction rate and ability to remove red blood cells from a whole blood sample.
  • cell lysing agent may also be desired to employ a cell lysing agent to facilitate the disruption the membrane of an erythrocyte and thereby boost the ability of the composition to separate the red blood cells.
  • a cell lysing agent is a surfactant, such as a nonionic, anionic, cationic, and/or amphoteric surfactant.
  • Suitable nonionic surfactants may include, for instance, alkyl polysaccharides, amine oxides, block copolymers, castor oil ethoxylates, ceto-oleyl alcohol ethoxylates, ceto-stearyl alcohol ethoxylates, decyl alcohol ethoxylates, dinoyl phenol ethoxylates, dodecyl phenol ethoxylates, end-capped ethoxylates, ether amine derivatives, ethoxylated alkanolamides, ethylene glycol esters, fatty acid alkanolamides, fatty alcohol alkoxylates, lauryl alcohol ethoxylates, mono-branched alcohol ethoxylates, natural alcohol ethoxylates, nonyl phenol ethoxylates, octyl phenol ethoxylates, oleyl amine ethoxylates, random copolymer alkoxylates, sorbitan
  • nonionic surfactants include, but are not limited to, methyl gluceth-10, PEG-20 methyl glucose distearate, PEG-20 methyl glucose sesquistearate, Cn -I5 pareth-20, ceteth-8, ceteth-12, dodoxynol-12, laureth-15, PEG-20 castor oil, polysorbate 20, steareth-20, polyoxyethylene-10 cetyl ether, polyoxyethylene-10 stearyl ether, polyoxyethylene-20 cetyl ether, polyoxyethylene-10 oleyl ether, polyoxyethylene-20 oleyl ether, an ethoxylated nonylphenol, ethoxylated octylphenol, ethoxylated dodecylphenol, or ethoxylated fatty (C 6 -C 22 ) alcohol, including 3 to 20 ethylene oxide moieties, polyoxyethylene-20 isohexadecyl ether, polyoxyethylene-23 glycerol laurate, poly
  • Alkyl glycoside nonionic surfactants may also be employed that are generally prepared by reacting a monosaccharide, or a compound hydrolyzable to a monosaccharide, with an alcohol such as a fatty alcohol in an acid medium.
  • an alcohol such as a fatty alcohol in an acid medium.
  • suitable alkyl glycosides include GlucoponTM 220, 225, 425, 600 and 625, all of which are available from Cognis Corp. of Cincinnati, Ohio.
  • GlucoponTM 220, 225 and 425 are examples of particularly suitable alkyl polyglycosides.
  • GlucoponTM 220 is an alkyl polyglycoside that contains an average of 1.4 glucosyl residues per molecule and a mixture of 8 and 10 carbon alkyl groups (average carbons per alkyl chain-9.1 ).
  • GlucoponTM 225 is a related alkyl polyglycoside with linear alkyl groups having 8 or 10 carbon atoms (average alkyl chain-9.1 carbon atoms) in the alkyl chain.
  • GlucoponTM 425 includes a mixture of alkyl polyglycosides that individually include an alkyl group with 8, 10, 12, 14 or 16 carbon atoms (average alkyl chain- 10.3 carbon atoms).
  • GlucoponTM 600 includes a mixture of alkyl polyglycosides that individually include an alkyl group with 12, 14 or 16 carbon atoms (average alkyl chain 12.8 carbon atoms).
  • GlucoponTM 625 includes a mixture of alkyl polyglycosides that individually include an alkyl group having 12, 14 or 18 carbon atoms (average alkyl chain 12.8 carbon atoms). Still other suitable alkyl glycosides are available from Dow Chemical Co. of Midland, Michigan under the TritonTM designation, e.g., TritonTM CG-110 and BG-10.
  • Exemplary anionic surfactants include alkyl sulfates, alkyl ether sulfates, alkyl ether sulfonates, sulfate esters of an alkylphenoxy polyoxyethylene ethanol, ⁇ -olefin sulfonates, ⁇ -alkoxy alkane sulfonates, alkylauryl sulfonates, alkyl monoglyceride sulfates, alkyl monoglyceride sulfonates, alkyl carbonates, alkyl ether carboxylates, fatty acids, sulfosuccinates, sarcosinates, octoxynol or nonoxynol phosphates, taurates, fatty taurides, fatty acid amide polyoxyethylene sulfates, isethionates, or mixtures thereof.
  • anionic surfactants include, but are not limited to, C 8 -Ci 8 alkyl sulfates, C 8 -Ci 8 fatty acid salts, C 8 -Ci 8 alkyl ether sulfates having one or two moles of ethoxylation, C 8 -Ci 8 alkamine oxides, C 8 -Ci 8 alkoyl sarcosinates, C 8 -Ci 8 sulfoacetates, C 8 -Ci 8 sulfosuccinates, C 8 -Ci 8 alkyl diphenyl oxide disulfonates, C 8 -Ci 8 alkyl carbonates, C 8 -Ci 8 alpha-olefin sulfonates, methyl ester sulfonates, and blends thereof.
  • the C 8 -Ci 8 alkyl group may be straight chain (e.g., lauryl) or branched (e.g., 2- ethylhexyl).
  • the cation of the anionic surfactant may be an alkali metal (e.g., sodium or potassium), ammonium, CrC 4 alkylammonium (e.g., mono-, di-, tri-), or CrC 3 alkanolammonium (e.g., mono-, di-, tri).
  • anionic surfactants may include, but are not limited to, lauryl sulfates, octyl sulfates, 2- ethylhexyl sulfates, lauramine oxide, decyl sulfates, tridecyl sulfates, cocoates, lauroyl sarcosinates, lauryl sulfosuccinates, linear C- 10 diphenyl oxide disulfonates, lauryl sulfosuccinates, lauryl ether sulfates (1 and 2 moles ethylene oxide), myristyl sulfates, oleates, stearates, tallates, ricinoleates, cetyl sulfates, and similar surfactants.
  • Amphoteric surfactants may also be employed, such as derivatives of secondary and tertiary amines having aliphatic radicals that are straight chain or branched, wherein one of the aliphatic substituents contains from about 8 to 18 carbon atoms and at least one of the aliphatic substituents contains an anionic water-solubilizing group, such as a carboxy, sulfonate, or sulfate group.
  • amphoteric surfactants include, but are not limited to, sodium 3- (dodecylamino)propionate, sodium 3-(dodecylamino)-propane-1 -sulfonate, sodium 2-(dodecylamino)ethyl sulfate, sodium 2-(dimethylamino)octadecanoate, disodium 3-(N-carboxymethyl-dodecylamino)propane-1 -sulfonate, disodium octadecyliminodiacetate, sodium 1-carboxymethyl-2-undecylimidazole, and sodium N, N-bis(2-hydroxyethyl)-2-sulfato-3-dodecoxypropylamine.
  • amphoteric surfactants include phosphobetaines and the phosphitaines.
  • amphoteric surfactants include, but are not limited to, sodium coconut N-methyl taurate, sodium oleyl N-methyl taurate, sodium tall oil acid N-methyl taurate, sodium palmitoyl N-methyl taurate, cocodimethylcarboxymethylbetaine, lauryldimethylcarboxymethylbetaine, lauryldimethylcarboxyethylbetaine, cetyldimethylcarboxymethylbetaine, lauryl-bis- (2-hydroxyethyl)carboxymethylbetaine, oleyldimethylgammacarboxypropylbetaine, lauryl-bis-(2-hydroxypropyl)-carboxyethylbetaine, cocoamidodimethylpropylsultaine, stearylamidodimethylpropylsultaine, laurylamido-bis-(2-hydroxyethyl)propyls
  • Cationic surfactants may also be employed in the present invention, such as alkyl dimethylamines, alkyl amidopropylamines, alkyl imidazoline derivatives, quatemized amine ethoxylates, quaternary ammonium compounds, etc.
  • Still other suitable cell lysing agents for use herein include biguanide and derivatives thereof, organic sulfur compounds, organic nitrogen compounds, phenyl and phenoxy compounds, phenolic compounds, aldehydes (e.g., glutaraldehyde or formaldehyde), glyoxal, parabens (e.g., ethyl paraben, propyl paraben, or methyl paraben), alcohols, such as aliphatic alcohols having from 1 to 16 carbon atoms, and preferably from 1 to 6 (e.g., methanol, ethanol, propanol, isopropanol, butanol, pentanol, octanol) and aromatic alcohols having from 6 to 30 total carbon atoms (e.g., naphtol), and mixtures thereof.
  • aldehydes e.g., glutaraldehyde or formaldehyde
  • parabens e.g., eth
  • the cell lysing agent is present in such an amount that the ratio of the unsaturated fatty acid (or ester thereof) to the cell lysing agent is from about 1 :1 up to about 30:1 , in some embodiments from about 5:1 to about 25:1 , and in some embodiments, from about 10:1 or 20:1.
  • the blood cell barrier composition may contain from about 0.001 wt.% to about 5 wt.%, in some embodiments from about 0.01 wt.% to about 2 wt.%, and in some embodiments, from about 0.05 wt.% to about 1 wt.% of unsaturated fatty acids (or esters thereof) by volume of the cell lysing agents.
  • the blood cell barrier composition may also contain one or more additional ingredients to impart a variety of different benefits.
  • the blood cell barrier composition may contain a chelating agent, which is a substance whose molecules can form one or more bonds with a metal ion.
  • a chelating agent is a substance whose molecules can form one or more bonds with a metal ion.
  • water often contains metal ions, such as calcium ions, that might react with anionic components (e.g., surfactants, acids, etc.) present within the blood cell barrier composition.
  • anionic components e.g., surfactants, acids, etc.
  • chelating agents that may be used in the blood cell barrier composition of the present invention include, but are not limited to, ethylenediamines, ethylenediaminetetraacetic acids (EDTA) acid and/or salts thereof, citric acids and/or salts thereof, glucuronic acids and/or salts thereof, polyphosphates, organophosphates, dimercaprols, and so forth.
  • EDTA ethylenediaminetetraacetic acids
  • citric acids and/or salts thereof citric acids and/or salts thereof
  • glucuronic acids and/or salts thereof polyphosphates, organophosphates, dimercaprols, and so forth.
  • the blood cell barrier composition may also include various other components as is well known in the art, such as agglutinating agents (e.g., lectin and derivatives thereof), binders, humectants, biocides or biostats, preservatives, electrolytic salts, pH adjusters, etc.
  • agglutinating agents e.g., lectin and derivatives thereof
  • binders e.g., binders, humectants, biocides or biostats, preservatives, electrolytic salts, pH adjusters, etc.
  • humectants include, for instance, ethylene glycol; diethylene glycol; glycerin; polyethylene glycol 200, 400, and 600; propane 1 ,3 diol; propylene-glycolmonomethyl ethers, such as Dowanol PM (Gallade Chemical Inc., Santa Ana, California); polyhydric alcohols; or combinations thereof.
  • the blood cell barrier composition its components are first typically dissolved or dispersed in a solvent.
  • a solvent for example, one or more of the above- mentioned components may be mixed with a solvent, either sequentially or simultaneously, to form a blood cell barrier composition that may be easily applied to a porous membrane.
  • Any solvent capable of dispersing or dissolving the components is suitable, for example water; alcohols such as ethanol or methanol; dimethylformamide; dimethyl sulfoxide; hydrocarbons such as pentane, butane, heptane, hexane, toluene and xylene; ethers such as diethyl ether and tetrahydrofuran; ketones and aldehydes such as acetone and methyl ethyl ketone; acids such as acetic acid and formic acid; and halogenated solvents such as dichloromethane and carbon tetrachloride; as well as mixtures thereof.
  • alcohols such as ethanol or methanol
  • dimethylformamide dimethyl sulfoxide
  • hydrocarbons such as pentane, butane, heptane, hexane, toluene and xylene
  • ethers such as diethyl ether and tetrahydrofur
  • the concentration of solvent in the blood cell barrier composition is generally high enough to allow easy application, handling, etc. If the amount of solvent is too large, however, the amount of unsaturated fatty acid (or ester thereof) deposited might be too low to provide the desired separation. Although the actual concentration of solvent employed will generally depend on the nature of the blood cell barrier composition and the membrane to which it is applied, it is nonetheless typically present in an amount from about 40 wt.% to about 99 wt.%, in some embodiments from about 50 wt.% to about 95 wt.%, and in some embodiments, from about 60 wt.% to about 90 wt.% of the blood cell barrier composition (prior to drying). A variety of techniques may be used for applying the blood cell barrier composition to a porous membrane.
  • the blood cell barrier composition may be applied using rotogravure or gravure printing, either direct or indirect (offset).
  • Gravure printing encompasses several well-known engraving techniques, such as mechanical engraving, acid-etch engraving, electronic engraving and ceramic laser engraving. Such printing techniques provide excellent control of the composition distribution and transfer rate. Gravure printing may provide, for example, from about 10 to about 1000 deposits per lineal inch of surface, or from about 100 to about 1 ,000,000 deposits per square inch. Each deposit results from an individual cell on a printing roll, so that the density of the deposits corresponds to the density of the cells.
  • a suitable electronic engraved example for a primary delivery zone is about 200 deposits per lineal inch of surface, or about 40,000 deposits per square inch.
  • Still another suitable contact printing technique that may be utilized in the present invention is "screen printing.”
  • Screen printing is performed manually or photomechanically.
  • the screens may include a silk or nylon fabric mesh with, for instance, from about 40 to about 120 openings per lineal centimeter.
  • the screen material is attached to a frame and stretched to provide a smooth surface.
  • the stencil is applied to the bottom side of the screen, i.e., the side in contact with a membrane upon which the composition is to be printed.
  • the blood cell barrier composition is painted onto the screen, and transferred by rubbing the screen (which is in contact with the substrate) with a squeegee.
  • Ink-jet printing techniques may also be employed in the present invention.
  • Ink-jet printing is a non-contact printing technique that involves forcing the ink through a tiny nozzle (or a series of nozzles) to form droplets that are directed toward the membrane.
  • Two techniques are generally utilized, i.e., "DOD" (Drop- On-Demand) or "continuous" ink-jet printing.
  • DOD Drop- On-Demand
  • continuous systems ink is emitted in a continuous stream under pressure through at least one orifice or nozzle. The stream is perturbed by a pressurization actuator to break the stream into droplets at a fixed distance from the orifice.
  • DOD systems use a pressurization actuator at each orifice to break the ink into droplets.
  • the pressurization actuator in each system may be a piezoelectric crystal, an acoustic device, a thermal device, etc.
  • the selection of the type of ink-jet system varies on the type of material to be printed from the print head. For example, conductive materials are sometimes required for continuous systems because the droplets are deflected electrostatically.
  • any other suitable application technique may be used in the present invention.
  • other suitable printing techniques may include, but not limited to, such as laser printing, thermal ribbon printing, piston printing, spray printing, flexographic printing, etc.
  • Still other suitable application techniques may include bar, roll, knife, curtain, spray, slot-die, dip-coating, drop-coating, extrusion, stencil application, striping, etc.
  • the blood cell barrier composition may sometimes be dried at a certain temperature to drive any solvent therefrom.
  • the membrane may be heated to a temperature of at least about 50 0 C, in some embodiments at least about 70 0 C, and in some embodiments, at least about 80 0 C.
  • the dried blood cell barrier composition may contain a solvent in an amount less than about 10% by weight, in some embodiments less than about 5% by weight, and in some embodiments, less than about 1 % by weight.
  • the blood cell barrier composition is generally applied to a porous membrane to form a barrier zone.
  • the barrier zone is positioned upstream from and in fluid communication with the detection zone of the lateral flow device.
  • a first porous membrane for example, may be provided as a separate material or pad that is positioned adjacent to a second porous membrane, which defines the detection zone.
  • the separated plasma may flow through the pores of the first porous membrane and then through the pores of the second porous membrane until reaching the detection zone.
  • the barrier zone may be formed on the same membrane as the detection zone. In this manner, the barrier zone of the present invention is integrated within the lateral flow device itself, which provides an efficient, simple, and cost effective method for separating red blood cells from a whole blood sample.
  • a single porous membrane defines both the barrier zone and detection zone. More specifically, a lateral flow device 20 is shown that contains a porous membrane 23 carried by an optional support 21.
  • the porous membrane 23 may be formed from any material as is known in the art.
  • the porous membrane 23 may be formed from synthetic or naturally occurring materials, such as polysaccharides (e.g., cellulose materials such as paper and cellulose derivatives, such as cellulose acetate and nitrocellulose); polyether sulfone; polyethylene; nylon; polyvinylidene fluoride (PVDF); polyester; polypropylene; silica; inorganic materials, such as deactivated alumina, glass, diatomaceous earth, MgSO 4 , or other inorganic finely divided material uniformly dispersed in a porous polymer matrix, with polymers such as vinyl chloride, vinyl chloride- propylene copolymer, and vinyl chloride-vinyl acetate copolymer; cloth, both naturally occurring (e.g., cotton) and synthetic (e.g., nylon or rayon); porous gels, such as silica gel, agarose, dextran, and gelatin; polymeric films, such as polyacrylamide; and so forth.
  • polysaccharides e.g.,
  • the porous membrane 23 is formed from nitrocellulose and/or polyether sulfone materials.
  • nitrocellulose refers to nitric acid esters of cellulose, which may be nitrocellulose alone, or a mixed ester of nitric acid and other acids, such as aliphatic carboxylic acids having from 1 to 7 carbon atoms.
  • the pores of the porous membrane 23 may have an average size of from about 1 micron to about 50 microns, in some embodiments from about 5 microns to about 30 microns, and in some embodiments from about 5 microns to about 15 microns.
  • the size and shape of the porous membrane 23 may also vary as is readily recognized by those skilled in the art.
  • a porous membrane strip may have a length of from about 10 to about 100 millimeters, in some embodiments from about 20 to about 80 millimeters, and in some embodiments, from about 40 to about 60 millimeters.
  • the width of the membrane strip may also range from about 0.5 to about 20 millimeters, in some embodiments from about 1 to about 15 millimeters, and in some embodiments, from about 2 to about 10 millimeters.
  • the thickness of the membrane strip is generally small enough to allow transmission-based detection.
  • the membrane strip may have a thickness less than about 500 micrometers, in some embodiments less than about 250 micrometers, and in some embodiments, less than about 150 micrometers.
  • the support 21 may be positioned directly adjacent to the porous membrane 23 as shown in Fig. 1 , or one or more intervening layers may be positioned between the porous membrane 23 and the support 21. If desired, the support 21 may be formed from a material that is transmissive to light, such as transparent or optically diffuse (e.g., transluscent) materials. Also, it is generally desired that the support 21 is liquid-impermeable so that fluid flowing through the membrane 23 does not leak through the support 21.
  • suitable materials for the support include, but are not limited to, glass; polymeric materials, such as polystyrene, polypropylene, polyester (e.g., Mylar® film), polybutadiene, polyvinylchloride, polyamide, polycarbonate, epoxides, methacrylates, and polymelamine; and so forth.
  • the support 21 is generally selected to have a certain minimum thickness. Likewise, the thickness of the support 21 is typically not so large as to adversely affect its optical properties.
  • the support 21 may have a thickness that ranges from about 100 to about 5,000 micrometers, in some embodiments from about 150 to about 2,000 micrometers, and in some embodiments, from about 250 to about 1 ,000 micrometers.
  • one suitable membrane strip having a thickness of about 125 micrometers may be obtained from Millipore Corp. of Bedford, Massachusetts under the name "SHF180UB25.”
  • the porous membrane 23 may be cast onto the support 21 , wherein the resulting laminate may be die-cut to the desired size and shape.
  • the porous membrane 23 may simply be laminated to the support 21 with, for example, an adhesive.
  • a nitrocellulose or nylon porous membrane is adhered to a Mylar® film.
  • An adhesive is used to bind the porous membrane to the Mylar® film, such as a pressure-sensitive adhesive.
  • Laminate structures of this type are believed to be commercially available from Millipore Corp. of Bedford, Massachusetts. Still other examples of suitable laminate device structures are described in U.S. Patent No. 5,075,077 to Durlev, IH 1 et a!., which is incorporated herein in its entirety by reference thereto for all purposes.
  • the device 20 may also contain an absorbent material 28 that is positioned adjacent to the membrane 23.
  • the absorbent material 28 assists in promoting capillary action and fluid flow through the membrane 23.
  • the absorbent material 28 receives fluid that has migrated through the entire porous membrane 23 and thus draws any unreacted components away from the detection region.
  • absorbent materials include, but are not limited to, nitrocellulose, cellulosic materials, porous polyethylene pads, glass fiber filter paper, and so forth.
  • the absorbent material may be wet or dry prior to being incorporated into the device. Pre-wetting may facilitate capillary flow for some fluids, but is not typically required. Also, as is well known in the art, the absorbent material may be treated with a surfactant to assist the wicking process.
  • the porous membrane 23 defines a barrier zone 35 that is configured to facilitate the separation of red blood cells from the whole blood sample.
  • the blood plasma is analyzed at a detection zone 31 , which is located downstream from the blood cell barrier zone 35.
  • the barrier zone 35 may provide any number of distinct regions (e.g., lines, dots, etc.).
  • the regions may be disposed in the form of lines in a direction that is substantially perpendicular to the flow of the test sample through the membrane 23.
  • the regions may be disposed in the form of lines in a direction that is substantially parallel to the flow of the test sample through the membrane 23.
  • the whole blood sample may be applied (such as with a lancet, needle, dropper, pipette, capillary device, etc.) directly to the barrier zone 35 or to a portion of the porous membrane 23 through which it may then travel in the direction illustrated by arrow "L" in Fig. 1 to reach the barrier zone 35.
  • a metering channel (not shown) may be formed in the membrane 23, such as described in U.S. Patent Application Publication No. 2006/0246600 to Yang, et al., which is incorporated herein in its entirety by reference thereto for all purposes.
  • the sample may be applied to the metering channel for subsequent transfer to the barrier zone 35.
  • the whole blood sample may first be applied to a separate sample application pad 24 located upstream from the barrier zone 35 and in fluid communication with the porous membrane 23.
  • a diluent may be employed that helps initiate flow of the sample in the direction of the detection zone 31. For example, upon application, the diluent may flow through the membrane 23 until reaching the sample application zone. The diluent then flows with the whole blood sample and helps carry it to the barrier zone 35 and the detection zone 31.
  • the diluent may be any material having a viscosity that is sufficiently low to allow movement of the fluid by capillary action and that supports a reaction between the analyte and any binding agents (e.g., does not interfere with antibody/antigen interaction).
  • the diluent contains water, a buffering agent; a salt (e.g., NaCI); a protein stabilizer (e.g., BSA, casein, trehalose, or serum); and/or a detergent (e.g., nonionic surfactant).
  • Representative buffering agents include, for example, phosphate-buffered saline (PBS) (e.g., pH of 7.2), 2-(N-morpholino) ethane sulfonic acid (MES) (e.g., pH of 5.3), HEPES buffer, TBS buffer, etc., and so forth.
  • PBS phosphate-buffered saline
  • MES 2-(N-morpholino) ethane sulfonic acid
  • HEPES buffer e.g., pH of 5.3
  • TBS buffer e.g., TBS buffer, etc.
  • the reagents may be disposed in a reagent zone located upstream from, downstream from, or at the location where the blood sample is applied.
  • a reagent zone 22 is employed that is formed from a separate material or pad (e.g., glass fiber pad).
  • the reagent zone may simply be formed on the porous membrane.
  • one particular embodiment of the present invention relies upon immunospecific reactions between binding pairs (e.g., antibodies and antigens) to detect the analyte in the whole blood sample.
  • Various immunoassay formats may also be used to test for the analyte.
  • a "sandwich" assay format is utilized in which the analyte has an affinity for the specific binding member of a conjugated probe and a receptive material in the detection zone.
  • the analyte typically has two or more binding sites (e.g., epitopes), one of which becomes occupied by the specific binding member of the conjugated probe.
  • the free binding site of the analyte may subsequently bind to the receptive material to form a new ternary sandwich complex.
  • the analyte may be detected using direct or indirect "competitive" assay formats.
  • the specific binding member of the conjugated probe may be the same as or an analog of the analyte.
  • the conjugated detection probe and the analyte thus compete for available binding sites of the receptive material.
  • the receptive material in the detection zone may be the same as or an analog of the analyte. The receptive material and the analyte thus compete for available binding sites of the conjugated probe.
  • any other assay format is also suitable for use in the present invention.
  • immunoassays generally employ a substance that is detectable either visually or by an instrumental device. Any substance generally capable of producing a signal that is detectable visually or by an instrumental device may be used as detection probes. Suitable detectable substances may include, for instance, luminescent compounds (e.g., fluorescent, phosphorescent, etc.); radioactive compounds; visual compounds (e.g., colored dye or metallic substance, such as gold); liposomes or other vesicles containing signal-producing substances; enzymes and/or substrates, and so forth. Other suitable detectable substances may be described in U.S. Patent Nos. 5,670,381 to Jou, et al.
  • the detectable substance is colored, the ideal electromagnetic radiation is light of a complementary wavelength. For instance, blue detection probes strongly absorb red light.
  • the detectable substance may be used alone or in conjunction with a particle (sometimes referred to as "beads" or "microbeads").
  • a particle sometimes referred to as "beads” or "microbeads”
  • naturally occurring particles such as nuclei, mycoplasma, plasmids, plastids, mammalian cells (e.g., erythrocyte ghosts), unicellular microorganisms (e.g., bacteria), polysaccharides (e.g., agarose), etc., may be used.
  • synthetic particles may also be utilized.
  • latex microparticles that are labeled with a fluorescent or colored dye are utilized.
  • the particles are typically formed from polystyrene, butadiene styrenes, styreneacrylic-vinyl terpolymer, polymethylmethacrylate, polyethylmethacrylate, styrene-maleic anhydride copolymer, polyvinyl acetate, polyvinylpyridine, polydivinylbenzene, polybutyleneterephthalate, acrylonitrile, vinylchloride-acrylates, and so forth, or an aldehyde, carboxyl, amino, hydroxyl, or hydrazide derivative thereof.
  • suitable particles may be described in U.S. Patent Nos. 5,670,381 to Jou, et al.; 5,252,459 to Tarcha, et al.; and U.S. Patent Publication No. 2003/0139886 to Bodzin, et al., which are incorporated herein in their entirety by reference thereto for all purposes.
  • Commercially available examples of suitable fluorescent particles include fluorescent carboxylated microspheres sold by Molecular Probes, Inc. under the trade names "FluoSphere” (Red 580/605) and "TransfluoSphere"
  • suitable colored, latex microparticles include carboxylated latex beads sold by Bang's Laboratory, Inc.
  • Metallic particles e.g., gold particles may also be utilized in the present invention.
  • the shape of the particles may generally vary.
  • the particles are spherical in shape.
  • other shapes are also contemplated by the present invention, such as plates, rods, discs, bars, tubes, irregular shapes, etc.
  • the size of the particles may also vary. For instance, the average size
  • the particles may range from about 0.1 nanometers to about 100 microns, in some embodiments, from about 1 nanometer to about 10 microns, and in some embodiments, from about 10 to about 100 nanometers.
  • the detection probes In performing an immunoassay, it is normally desired to modify the detection probes so that they are more readily able to bind to the analyte.
  • the detection probes may be modified with certain specific binding members that are adhered thereto to form conjugated probes.
  • Specific binding members generally refer to a member of a specific binding pair, i.e., two different molecules where one of the molecules chemically and/or physically binds to the second molecule.
  • immunoreactive specific binding members may include antigens, haptens, aptamers, antibodies (primary or secondary), and complexes thereof, including those formed by recombinant DNA methods or peptide synthesis.
  • An antibody may be a monoclonal or polyclonal antibody, a recombinant protein or a mixture(s) or fragment(s) thereof, as well as a mixture of an antibody and other specific binding members.
  • the details of the preparation of such antibodies and their suitability for use as specific binding members are well known to those skilled in the art.
  • specific binding pairs include but are not limited to, biotin and avidin (or derivatives thereof), biotin and streptavidin, carbohydrates and lectins, complementary nucleotide sequences (including probe and capture nucleic acid sequences used in DNA hybridization assays to detect a target nucleic acid sequence), complementary peptide sequences including those formed by recombinant methods, effector and receptor molecules, hormone and hormone binding protein, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, and so forth.
  • specific binding pairs may include members that are analogs of the original specific binding member.
  • a derivative or fragment of the analyte may be used so long as it has at least one epitope in common with the analyte.
  • the specific binding members may be attached to the detection probes using any of a variety of well-known techniques. For instance, covalent attachment of the specific binding members to the detection probes (e.g., particles) may be accomplished using carboxylic, amino, aldehyde, bromoacetyl, iodoacetyl, thiol, epoxy and other reactive or linking functional groups, as well as residual free radicals and radical cations, through which a protein coupling reaction may be accomplished.
  • a surface functional group may also be incorporated as a functionalized co-monomer because the surface of the detection probe may contain a relatively high surface concentration of polar groups.
  • detection probes are often functionalized after synthesis, such as with poly(thiophenol), the detection probes may be capable of direct covalent linking with a protein without the need for further modification.
  • the first step of conjugation is activation of carboxylic groups on the probe surface using carbodiimide.
  • the activated carboxylic acid groups are reacted with an amino group of an antibody to form an amide bond.
  • the activation and/or antibody coupling may occur in a buffer, such as phosphate-buffered saline (PBS) (e.g., pH of 7.2) or 2-(N-morpholino) ethane sulfonic acid (MES) (e.g., pH of 5.3).
  • PBS phosphate-buffered saline
  • MES 2-(N-morpholino) ethane sulfonic acid
  • ethanolamine for instance, to block any remaining activated sites.
  • this process forms a conjugated detection probe, where the antibody is covalently attached to the probe.
  • other attachment techniques such as physical adsorption, may also be utilized in the present invention. Referring again to Fig.
  • a receptive material may also be non- diffusively immobilized within the detection zone 31 that is capable of binding to the analyte and/or to the specific binding member of the conjugated detection probes, depending on the assay format employed.
  • the receptive material may be selected from the same materials as the specific binding members described above, including, for instance, antigens; haptens; antibody-binding proteins, such as protein A, protein G, or protein A/G; neutravidin (a deglycosylated avidin derivative), avidin (a highly cationic 66,000-dalton glycoprotein), streptavidin (a nonglycosylated 52,800-dalton protein), or captavidin (a nitrated avidin derivative); primary or secondary antibodies, and derivatives or fragments thereof.
  • the receptive material is an antibody specific to an antigen within the test sample.
  • the receptive material serves as a stationary binding site for complexes formed between the analyte and the conjugated detection probes.
  • analytes such as antibodies, antigens, etc.
  • analytes typically have two or more binding sites (e.g., epitopes).
  • binding sites e.g., epitopes
  • the free binding site of the analyte may bind to the immobilized first receptive material.
  • the complexed probes form a new ternary sandwich complex.
  • the detection zone 31 may provide any number of distinct detection regions so that a user may better determine the concentration of one or more analytes within a test sample.
  • Each region may contain the same receptive materials, or may contain different receptive materials.
  • the zone may include two or more distinct regions (e.g., lines, dots, etc.).
  • the regions may be disposed in the form of lines in a direction that is substantially perpendicular to the flow of the test sample through the assay device 20.
  • the regions may be disposed in the form of lines in a direction that is substantially parallel to the flow of the test sample through the assay device 20.
  • the lateral flow device 20 may also define various other zones for enhancing detection accuracy, such as internal calibration zones, control zones, etc. Examples of such additional zones are described in more detail in U.S. Patent Application Publication Nos. 2006/0223193 to Song, et al.; 2006/0246601 to Song, et al.; and 2007/0048807 to Song, which are incorporated herein in their entirety by reference thereto for all purposes.
  • the intensity of any signals produced at the detection zone 31 may be measured with an optical reader.
  • the actual configuration and structure of the optical reader may generally vary as is readily understood by those skilled in the art.
  • optical detection techniques include, but are not limited to, luminescence (e.g., fluorescence, phosphorescence, etc.), absorbance (e.g., fluorescent or non- fluorescent), diffraction, etc.
  • luminescence e.g., fluorescence, phosphorescence, etc.
  • absorbance e.g., fluorescent or non- fluorescent
  • diffraction etc.
  • One suitable reflectance spectrophotometer is described, for instance, in U.S. Patent App. Pub. No.
  • a reflectance-mode spectrofluorometer may be used to detect the intensity of a fluorescence signal. Suitable spectrofluorometers and related detection techniques are described, for instance, in U.S. Patent App. Pub. No. 2004/0043502 to Song, et al., which is incorporated herein in its entirety by reference thereto for all purposes.
  • a transmission-mode detection system may also be used to signal intensity.
  • a device of the present invention may generally have any configuration desired, and need not contain all of the components described above.
  • Various other device configurations are described in U.S. Patent Nos. 5,395,754 to Lambotte, et al.; 5,670,381 to Jou, et al.; and 6,194,220 to Malick, et a!., which are incorporated herein in their entirety by reference thereto for all purposes.
  • a circle of Whatman filter paper (Qualitative 18.5cm) was cut into strips (16 cm x 2 cm).
  • a thin line of linoleic acid was placed 8 cm from the bottom end of the strip using a syringe with needle, to lay down a thin line of liquid (approximately 5- 10 ⁇ l).
  • a drop (20 ⁇ l) of fresh human blood was placed onto the strip 4 cm up from the bottom.
  • a control strip was prepared in a similar manner except no linoleic acid was placed on the control strip. The strips were then attached to a glass rod, being 6cm away from each other, using scotch tape.
  • the strips were placed into a tall beaker (2 liter volume) containing deionized water (50 ml) in such a manner that the bottom end of the paper strips just entered the water. The water wicked up the vertically hanging strips. The blood was observed to move up the strips being eluted by the water. On the control strip, the blood was observed to wick up the entire strip over 30 minutes time unhindered, leaving a light trail of red brown color.
  • the blood spot was observed to halt at the line where the linoleic acid had been placed.
  • the system was allowed to run for another 20 minutes after which time the strips were taken out and allowed to air dry. Both strips were then sprayed with a ninhydrin spray to detect amino acids. Both strips visually showed the presence of amino acids by developing a purple color. The control had traces present along the length and a strong presence where the blood spot had stopped.
  • the red/brown spot had stopped at the linoleic acid line, but the ninhydrin spray visually indicated the presence of amino acids after the line indicating how effectively the linoleic acid had halted the hemoglobin and blood cell membranes (no red/brown trail or spot), but had allowed the other useful biomolecular analytes to pass through undeterred.
  • Example 1 The experiment described in Example 1 was repeated but using nitrocellulose lateral flow membrane strips (Bangs Laboratories Inc., Fishers Indiana) in place of the paper strips. The same procedure was conducted and at the end of the flow period (20 minutes) the strips were allowed to dry. Similar to the strips in Example 1 , the blood spot was halted at the linoleic acid line. In contrast, the control strip allowed the blood to travel up the entire length of the strip. The strips were then sprayed with phenolphthalin solution followed by a 3% solution of hydrogen peroxide in water (a spot test for traces of dried blood and hemoglobin; Ervin Jungreis "Spot test analysis” 2 nd edition, John Wiley & Sons, Inc. NY 1997).
  • the entire length of the strip gave a visual indication (formation of pink color) for the presence of dried blood and/or hemoglobin with the majority of it being at the finish end of the strip.
  • the strip with the linoleic acid line no pink color developed, thereby indicating that there was no blood or hemoglobin beyond the line containing linoleic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un dispositif à flux latéral pour l'analyse d'un échantillon de sang entier. Plus spécifiquement, le dispositif à flux latéral contient une membrane poreuse qui définie une zone de barrière pour séparer les globules rouges du plasma sanguin (notamment un plasma duquel ont été retirés les facteurs de coagulation), ce dernier pouvant ensuite s'écouler dans une zone de détection successive pour analyse. La zone de barrière est formée d'une composition faisant barrière aux globules rouges qui comprend un acide gras aliphatique insaturé ou l'un de ses esters. Sans souhaiter se restreindre à une théorie, les présents inventeurs pensent que ces molécules d'acide gras aliphatique insaturé subissent une auto-oxydation en présence d'air et d'hémoglobine en libérant des peroxydes (par exemple, peroxyde d'hydrogène) par saturation oxydante des doubles liaisons. On pense que les peroxydes libérés induisent quant à eux la formation d'échinocytes ou cellules sanguines crénelées. Les globules rouges crénelés sont déformés et moins flexibles et malléables que les globules rouges normaux, ce qui les rend moins aptes à pénétrer dans les pores de la membrane poreuse du dispositif à flux latéral. Par conséquent, les cellules plus rigides, moins flexibles ne peuvent se déplacer facilement dans les pores et se retrouvent piégées à la surface de la membrane, tandis que les composants liquides de l'échantillon s'écoulent et pénètrent à travers la membrane vers la zone de détection pour analyse.
PCT/IB2008/053708 2007-11-30 2008-09-12 Barrière contre les cellules sanguines pour un dispositif à flux latéral WO2009069017A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/948,127 US8535617B2 (en) 2007-11-30 2007-11-30 Blood cell barrier for a lateral flow device
US11/948,127 2007-11-30

Publications (1)

Publication Number Publication Date
WO2009069017A1 true WO2009069017A1 (fr) 2009-06-04

Family

ID=40675912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/053708 WO2009069017A1 (fr) 2007-11-30 2008-09-12 Barrière contre les cellules sanguines pour un dispositif à flux latéral

Country Status (2)

Country Link
US (1) US8535617B2 (fr)
WO (1) WO2009069017A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127833A1 (fr) 2016-01-22 2017-07-27 Affimedix, Inc. Dispositif de détection de métabolites de la vitamine d
CN108828220A (zh) * 2018-03-29 2018-11-16 杭州泰熙生物技术有限公司 一种检测保健品中苯二氮卓类物质的检测卡及其制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2725977A1 (fr) * 2008-05-27 2009-12-03 Zbx Corporation Membrane analytique enzymatique, dispositif et procede de test
US8586697B2 (en) * 2010-04-09 2013-11-19 Basf Se Coatings repairable by introduction of energy
WO2012118494A1 (fr) 2011-03-01 2012-09-07 Empire Technology Development Llc Analyse du liquide menstruel
US20120264137A1 (en) * 2011-04-18 2012-10-18 Indian Institute Of Science Techniques for bufferless lysing of cells and separation of cellular components using modified membranes
WO2012178187A1 (fr) * 2011-06-23 2012-12-27 Paul Yager Modélisation de réactif dans des analyseurs de capillarité, et systèmes et procédés associés
EP2948249A1 (fr) 2013-01-22 2015-12-02 University of Washington through its Center for Commercialization Délivrance séquentielle de volumes de fluide et dispositifs, systèmes et procédés associés
US9482675B1 (en) * 2013-07-31 2016-11-01 University Of Kentucky Research Foundation Methods and systems for prognosis and diagnosis of brain damage
US10001480B2 (en) * 2014-01-31 2018-06-19 Jan J. Dubowski Photo-electrochemical biosensor and semiconductor heterostructure-based sensing method
US10983119B2 (en) 2016-01-25 2021-04-20 General Electric Company Device for rapid diagnostic tests to detect antigens with improved sensitivity
US10725031B1 (en) 2017-04-26 2020-07-28 Conquerab Inc. Reflux device for detection of analytes in samples

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939331A (en) * 1992-03-10 1999-08-17 Quidel Corporation Red blood cell separation means for specific binding assays
WO2005117556A2 (fr) * 2004-06-02 2005-12-15 Relia Diagnostic Systems, Llc Systeme et analyse quantitative de flux lateral
WO2007027198A1 (fr) * 2005-08-31 2007-03-08 Kimberly-Clark Worldwide, Inc. Technique de détection des nitrites

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3552928A (en) * 1967-07-19 1971-01-05 Miles Lab Whole blood separation means and test system using same
US3962436A (en) * 1969-06-03 1976-06-08 Sumitomo Chemical Company, Limited Pharmaceutical compositions having controlled rate of gastro-intestinal absorption
US3772076A (en) * 1970-01-26 1973-11-13 Hercules Inc Reaction products of epihalohydrin and polymers of diallylamine and their use in paper
US3700623A (en) * 1970-04-22 1972-10-24 Hercules Inc Reaction products of epihalohydrin and polymers of diallylamine and their use in paper
SE388694B (sv) * 1975-01-27 1976-10-11 Kabi Ab Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar
US4235601A (en) * 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
DE3029579C2 (de) * 1980-08-05 1985-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Mittel zur Abtrennung von Plasma oder Serum aus Vollblut
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB2090659A (en) 1981-01-02 1982-07-14 Instrumentation Labor Inc Analytical device
US4442204A (en) * 1981-04-10 1984-04-10 Miles Laboratories, Inc. Homogeneous specific binding assay device and preformed complex method
DE3464252D1 (en) * 1983-06-03 1987-07-23 Hoffmann La Roche Labelled molecules for fluorescence immunoassays and processes and intermediates for their preparation
US4537657A (en) * 1983-08-26 1985-08-27 Hercules Incorporated Wet strength resins
US5310687A (en) * 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US5585279A (en) * 1986-01-23 1996-12-17 Davidson; Robert S. Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium
US5591581A (en) * 1986-04-30 1997-01-07 Igen, Inc. Electrochemiluminescent rhenium moieties and methods for their use
DE3789430T2 (de) * 1986-06-17 1994-10-27 Baxter Diagnostics Inc Homogenes fluortestverfahren mit abstoss des fluorzenten hintergrundes.
US4810470A (en) * 1987-06-19 1989-03-07 Miles Inc. Volume independent diagnostic device
US4987085A (en) * 1987-06-22 1991-01-22 Chemtrak Inc. Blood filtering metering device
SE8703682L (sv) * 1987-09-24 1989-03-25 Wallac Oy Homogen bestaemningsmetod som utnyttjar affinitetsreaktioner
US5670381A (en) * 1988-01-29 1997-09-23 Abbott Laboratories Devices for performing ion-capture binding assays
US5075077A (en) * 1988-08-02 1991-12-24 Abbott Laboratories Test card for performing assays
US5252459A (en) * 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
US5416000A (en) * 1989-03-16 1995-05-16 Chemtrak, Inc. Analyte immunoassay in self-contained apparatus
US5234813A (en) * 1989-05-17 1993-08-10 Actimed Laboratories, Inc. Method and device for metering of fluid samples and detection of analytes therein
US5306623A (en) * 1989-08-28 1994-04-26 Lifescan, Inc. Visual blood glucose concentration test strip
AU640162B2 (en) * 1989-08-28 1993-08-19 Lifescan, Inc. Blood separation and analyte detection techniques
US5326692B1 (en) * 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
US5166051A (en) * 1990-08-08 1992-11-24 Genesis Labs, Inc. Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes
US5208535A (en) * 1990-12-28 1993-05-04 Research Development Corporation Of Japan Mr position detecting device
DE69220871T2 (de) * 1991-10-03 1997-11-20 Bayer Ag Vorrichtung und Verfahren zur Auftrennung und Analyse von Vollblut
US5271839A (en) 1992-04-14 1993-12-21 Millipore Corporation Patterned porous polymeric product and process
WO1994001774A1 (fr) * 1992-07-02 1994-01-20 Erkki Soini Methode d'analyse biospecifique portant sur plusieurs parametres
US5395754A (en) * 1992-07-31 1995-03-07 Hybritech Incorporated Membrane-based immunoassay method
IT1272109B (it) * 1993-03-19 1997-06-11 Eniricerche Spa Processo per la preparazione di apg
US5464741A (en) * 1993-10-08 1995-11-07 Henwell, Inc. Palladium (II) octaethylporphine alpha-isothiocyanate as a phosphorescent label for immunoassays
US5589399A (en) * 1994-10-21 1996-12-31 First Medical, Inc. System and method for plasma separation and measurement
US5866434A (en) * 1994-12-08 1999-02-02 Meso Scale Technology Graphitic nanotubes in luminescence assays
US5725774A (en) * 1995-04-07 1998-03-10 Lxn Corp. Whole blood separation method and devices using the same
EP0832430B1 (fr) * 1995-05-09 2006-07-26 Beckman Coulter, Inc. Dispositifs et procedes de separation des composants cellulaires du sang d'avec la partie liquide
US5981294A (en) * 1995-11-29 1999-11-09 Metrika, Inc. Device for blood separation in a diagnostic device
US6551791B1 (en) * 1995-12-21 2003-04-22 University Of Florida Rapid diagnostic method for distinguishing allergies and infections and nasal secretion collection unit
US5753497A (en) * 1995-12-22 1998-05-19 Universal Health Watch Inc Diagnostic assay providing blood separation
US6004530A (en) * 1996-06-04 1999-12-21 Roche Diagnostics Gmbh Use of metallo-porphyrin conjugates for the detection of biological substances
US6444423B1 (en) * 1996-06-07 2002-09-03 Molecular Dynamics, Inc. Nucleosides comprising polydentate ligands
US5770543A (en) * 1996-09-06 1998-06-23 Henkel Corporation Agricultural compositions comprising alkyl polyglycosides and fatty acids
US6194220B1 (en) * 1996-09-25 2001-02-27 Becton, Dickinson And Company Non-instrumented assay with quantitative and qualitative results
US5922537A (en) * 1996-11-08 1999-07-13 N.o slashed.AB Immunoassay, Inc. Nanoparticles biosensor
JPH10335096A (ja) 1997-06-03 1998-12-18 Hitachi Ltd プラズマ処理装置
US6613583B1 (en) * 1997-06-27 2003-09-02 Igen International, Inc. Electrochemiluminescent label based on multimetallic assemblies
HUP0102458A2 (hu) 1997-11-05 2001-11-28 American Bio Medica Corporation Többszörös kábítószer vizsgálati kártya kábítószer használatának vizsgálatára szolgáló folyadékminták számára, valamint eljárás ilyen vizsgálati kártyák előállítására
US6060256A (en) * 1997-12-16 2000-05-09 Kimberly-Clark Worldwide, Inc. Optical diffraction biosensor
US6030840A (en) * 1998-06-15 2000-02-29 Nen Life Sciences, Inc. Neutral enhancement of lanthanides for time resolved fluorescence
US6922576B2 (en) * 1998-06-19 2005-07-26 Becton, Dickinson And Company Micro optical sensor device
US7640083B2 (en) * 2002-11-22 2009-12-29 Monroe David A Record and playback system for aircraft
DE19849008A1 (de) * 1998-10-23 2000-04-27 Roche Diagnostics Gmbh Spreitschichten, Netzmittel zu ihrer Herstellung und deren Verwendung in Teststreifen
FI982422A0 (fi) * 1998-11-09 1998-11-09 Arctic Diagnostics Oy Porfyriiniyhdisteitä, niiden konjugaatit sekä määritysmenetelmiä pohjautuen näiden konjugaattien käyttöön
US6261779B1 (en) * 1998-11-10 2001-07-17 Bio-Pixels Ltd. Nanocrystals having polynucleotide strands and their use to form dendrimers in a signal amplification system
WO2000050891A1 (fr) 1999-02-26 2000-08-31 Fertility Acoustics Inc. Bandelette d'analyse dotee d'une cellule pour fluide et procede d'analyse d'un echantillon
US6585939B1 (en) * 1999-02-26 2003-07-01 Orchid Biosciences, Inc. Microstructures for use in biological assays and reactions
WO2000078917A1 (fr) 1999-06-18 2000-12-28 Umedik, Inc. Dispositif et procede d'analyse d'un echantillon biologique
WO2001017797A1 (fr) 1999-09-10 2001-03-15 Caliper Technologies Corp. Procedes et dispositifs de microfabrication
US20030113528A1 (en) * 1999-09-17 2003-06-19 Wilson Moya Patterned porous structures
US6365417B1 (en) * 2000-02-09 2002-04-02 A-Fem Medical Corporation Collection device for lateral flow chromatography
US6706159B2 (en) * 2000-03-02 2004-03-16 Diabetes Diagnostics Combined lancet and electrochemical analyte-testing apparatus
WO2001098785A2 (fr) 2000-06-19 2001-12-27 Arizona Board Of Regents Microcircuit pour dosage immunologique base sur l'ecoulement rapide
US20020036170A1 (en) * 2000-08-11 2002-03-28 Harvey Michael A. Lateral flower plasma separation device
WO2003000897A2 (fr) 2001-06-22 2003-01-03 Syngenta Participations Ag Identification et caracterisation de genes de transporteurs de phosphate
GB0115588D0 (en) 2001-06-26 2001-08-15 Coates Brothers Plc Novel compounds for use as photoinitiators
EP1417491A4 (fr) * 2001-07-18 2004-08-11 Siliang Zhou Bande d'essai pour dosage a ecoulement lateral d'un echantillon renfermant des cellules entieres
EP1432976A4 (fr) * 2001-09-05 2007-11-28 Genicon Sciences Corp Dispositif pour la lecture de signaux emis par des particules a dispersion de la lumiere de resonance utilisees comme marqueurs
US7244393B2 (en) * 2001-12-21 2007-07-17 Kimberly-Clark Worldwide, Inc. Diagnostic device and system
AU2002357754A1 (en) 2001-12-24 2003-07-24 Kimberly-Clark Worldwide, Inc. Flow-through assay with an internal calibration system using polyelectrolyte
US8367013B2 (en) * 2001-12-24 2013-02-05 Kimberly-Clark Worldwide, Inc. Reading device, method, and system for conducting lateral flow assays
US20030119203A1 (en) * 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
US7001715B2 (en) * 2002-02-28 2006-02-21 Biopure Corporation Purification of red blood cells by separation and diafiltration
EP1517996A4 (fr) * 2002-05-01 2005-10-26 Polymer Technology Systems Inc Bande d'essai et procede permettant de determiner la concentration de creatinine dans un fluide corporel
DE10222979B4 (de) 2002-05-23 2006-06-08 Sartorius Ag Verfahren zur Verstärkung eines Signals
AU2003302137A1 (en) * 2002-07-15 2004-06-15 Technical Instrument San Francisco Quality control of assays
US7314763B2 (en) * 2002-08-27 2008-01-01 Kimberly-Clark Worldwide, Inc. Fluidics-based assay devices
US7285424B2 (en) * 2002-08-27 2007-10-23 Kimberly-Clark Worldwide, Inc. Membrane-based assay devices
US7256053B2 (en) * 2002-10-24 2007-08-14 Nanogen, Inc. Diagnostic device for analyte detection
US20040087034A1 (en) * 2002-10-30 2004-05-06 Ching Ho Lien Test strip
US20040106190A1 (en) * 2002-12-03 2004-06-03 Kimberly-Clark Worldwide, Inc. Flow-through assay devices
US20040121334A1 (en) * 2002-12-19 2004-06-24 Kimberly-Clark Worldwide, Inc. Self-calibrated flow-through assay devices
DE10346417A1 (de) * 2003-10-07 2005-06-02 Roche Diagnostics Gmbh Analytisches Testelement umfassend ein Netzwerk zur Bildung eines Kapillarkanals
US20050136500A1 (en) * 2003-12-19 2005-06-23 Kimberly-Clark Worldwide; Inc. Flow-through assay devices
US7858384B2 (en) * 2005-04-29 2010-12-28 Kimberly-Clark Worldwide, Inc. Flow control technique for assay devices
US7803319B2 (en) * 2005-04-29 2010-09-28 Kimberly-Clark Worldwide, Inc. Metering technique for lateral flow assay devices
US7829347B2 (en) * 2005-08-31 2010-11-09 Kimberly-Clark Worldwide, Inc. Diagnostic test kits with improved detection accuracy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939331A (en) * 1992-03-10 1999-08-17 Quidel Corporation Red blood cell separation means for specific binding assays
WO2005117556A2 (fr) * 2004-06-02 2005-12-15 Relia Diagnostic Systems, Llc Systeme et analyse quantitative de flux lateral
WO2007027198A1 (fr) * 2005-08-31 2007-03-08 Kimberly-Clark Worldwide, Inc. Technique de détection des nitrites

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127833A1 (fr) 2016-01-22 2017-07-27 Affimedix, Inc. Dispositif de détection de métabolites de la vitamine d
US11073524B2 (en) 2016-01-22 2021-07-27 Affimedix, Inc. Device for detection of vitamin D metabolites
EP3954376A1 (fr) 2016-01-22 2022-02-16 Affimedix, Inc. Procédé de quantification des métabolites de la vitamine d
CN108828220A (zh) * 2018-03-29 2018-11-16 杭州泰熙生物技术有限公司 一种检测保健品中苯二氮卓类物质的检测卡及其制备方法
CN108828220B (zh) * 2018-03-29 2021-07-09 杭州泰熙生物技术有限公司 一种检测保健品中苯二氮卓类物质的检测卡及其制备方法

Also Published As

Publication number Publication date
US8535617B2 (en) 2013-09-17
US20090142229A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
US8535617B2 (en) Blood cell barrier for a lateral flow device
EP2088929B1 (fr) Dispositif d'envoi à écoulement latéral
EP1960785B1 (fr) Bande et procede de dosage pour dispositifs d analyse de debit lateral
EP1875241B1 (fr) Technique de mesure pour appareils de dosage a ecoulement lateral
EP1960782B1 (fr) Technique de dosage pour dispositifs d analyse a ecoulement lateral
US8124421B2 (en) Flow control technique for assay devices
US20060019406A1 (en) Lateral flow device for the detection of large pathogens
KR101254512B1 (ko) 면역 크로마토그래피용 시험구 및 이것을 사용한 반정량방법
US20210148906A1 (en) Lateral flow immunoassay device with separation membrane
EP1723423A1 (fr) Dispositif d'echantillonnage et son procede d'utilisation
KR100485564B1 (ko) 크로마토그래피 측정 장치
JP6357616B2 (ja) シート状免疫学的検査具

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08807641

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08807641

Country of ref document: EP

Kind code of ref document: A1